2 Houston startups make strategic hires

short stories

Two Houstonians have been named to the C-suites of growing startups. Photos courtesy

A pair of Houston tech startups have recently announced new appointments to their leadership staff. A digital supply chain commerce company named a new CFO, while an Irish health tech company has named its new Houston-based leader.

GoExpedi names new CFO

Jorge Ordonez is the newly named CFO for GoExpedi. Photo courtesy of GoExpedi

Houston-based GoExpedi, an innovative end-to-end digital supply chain and data analytics solutions company, named Jorge Ordonez as CFO for the company.

"With our rapidly accelerating growth, ongoing investment activity and new industrial customers coming online, it was crucial that we bring on board an experienced financial leader who can help us successfully scale at a fast pace," says Tim Neal, GoExpedi CEO, in a news release. "Jorge led one of the top medical equipment providers in the country as well as a leading industrial technology solutions provider. We'll greatly benefit from his diverse financial experience, helping us to become the leading digital industrial supply chain and data analytics providers in North America."

Ordonez brings 25 years of finance and accounting experience across industries, including 10 years in distribution and logistics. His most recent position was CFO at US Med-Equip, a medical equipment provider.

"I am honored to join GoExpedi, one of the most innovative industrial supply chain and data solutions providers out there, at this time of rapid growth," says Ordonez in the release. "I look forward to working closely with GoExpedi's leadership team to support sustained financial success as the company expands into different geographies and sectors. My goals are to help the company continue its financial success and build optimized financial decision-making models and processes that will equip the company to scale and expand capital availability to continue its growth trajectory."

Health tech startup with US operations in Houston names new CEO

Benjamin A. Hertzog will lead Intelligent Implants through its next phase of development. Photo courtesy of Intelligent Implants

Benjamin A. Hertzog, entrepreneur in residence at Johnson and Johnson’s Center for Device Innovation at the Texas Medical Center, has a new title. Last month, Hertzog was named CEO of Intelligent Implants, a development-stage digital medicine and orthopedics startup based in Ireland with its United States operations based in Houston.

“Ben joined Intelligent Implants as Executive Chairman of the Board in 2020, and his broad experience in complex Class-III medical devices, leadership, and exceptional track record made it an obvious choice to have Ben join us at the helm of the company,” says John Zellmer, Intelligent Implants co-founder and founding CEO, in a news release. “Ben has the skills and credibility to guide Intelligent Implants as we navigate through the next stage of clinical and commercial activities. We look forward to his leadership as we continue to achieve key milestones.”

Zellmer will transition into the role of COO while Hertzog is tasked with leading product development, as well as clinical, and commercial activities for the company’s novel and proprietary smart orthopedic implant platform.

With more than 20 years of experience in healthcare and life sciences as an engineer, investor, and entrepreneur, Hertzog has founded medical device startup, Procyrion, leading the cardiac device company through Series C financing, product development, animal studies, strategic investment, and human clinical trials. He also served as managing director of AlphaDev (now Fannin Partners), an early-stage venture development firm.

“I am thrilled to work with John and the entire Intelligent Implants team as we make progress towards bringing this novel technology platform to the market,” says Hertzog. “Throughout my career, I’ve been driven by and focused on bringing innovative medical device therapies to the market, and I believe that SmartFuse represents the future of medical devices; smart connected implants that provide therapeutic benefits and real-time data to support clinical decision making. Ultimately, I believe these implants will have significant advantages to traditional implants in addressing unmet clinical needs and improving patient outcomes.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

3 Houston startups named most innovative in Texas by LexisNexis

report card

Three Houston companies claimed spots on LexisNexis's 10 Most Innovative Startups in Texas report, with two working in the geothermal energy space.

Sage Geosystems claimed the No. 3 spot on the list, and Fervo Energy followed closely behind at No. 5. Fintech unicorn HighRadius rounded out the list of Houston companies at No. 8.

LexisNexis Intellectual Property Solutions compiled the report. It was based on each company's Patent Asset Index, a proprietary metric from LexisNexis that identifies the strength and value of each company’s patent assets based on factors such as patent quality, geographic scope and size of the portfolio.

Houston tied with Austin, each with three companies represented on the list. Caris Life Sciences, a biotechnology company based in Dallas, claimed the top spot with a Patent Asset Index more than 5 times that of its next competitor, Apptronik, an Austin-based AI-powered humanoid robotics company.

“Texas has always been fertile ground for bold entrepreneurs, and these innovative startups carry that tradition forward with strong businesses based on outstanding patent assets,” Marco Richter, senior director of IP analytics and strategy for LexisNexis Intellectual Property Solutions, said in a release. “These companies have proven their innovation by creating the most valuable patent portfolios in a state that’s known for game-changing inventions and cutting-edge technologies.We are pleased to recognize Texas’ most innovative startups for turning their ideas into patented innovations and look forward to watching them scale, disrupt, and thrive on the foundation they’ve laid today.”

This year's list reflects a range in location and industry. Here's the full list of LexisNexis' 10 Most Innovative Startups in Texas, ranked by patent portfolios.

  1. Caris (Dallas)
  2. Apptronik (Austin)
  3. Sage Geosystems (Houston)
  4. HiddenLayer (Austin)
  5. Fervo Energy (Houston)
  6. Plus One Robotics (San Antonio)
  7. Diligent Robotics (Austin)
  8. HighRadius (Houston)
  9. LTK (Dallas)
  10. Eagle Eye Networks (Austin)

Sage Geosystems has partnered on major geothermal projects with the United States Department of Defense's Defense Innovation Unit, the U.S. Air Force and Meta Platforms. Sage's 3-megawatt commercial EarthStore geothermal energy storage facility in Christine, Texas, was expected to be completed by the end of last year.

Fervo Energy fully contracted its flagship 500 MW geothermal development, Cape Station, this spring. Cape Station is currently one of the world’s largest enhanced geothermal systems (EGS) developments, and the station will begin to deliver electricity to the grid in 2026. The company was recently named North American Company of the Year by research and consulting firm Cleantech Group and came in at No. 6 on Time magazine and Statista’s list of America’s Top GreenTech Companies of 2025. It's now considered a unicorn, meaning its valuation as a private company has surpassed $1 billion.

Meanwhile, HighRadius announced earlier this year that it plans to release a fully autonomous finance platform for the "office of the CFO" by 2027. The company reached unicorn status in 2020.

---

This article originally appeared on Energy Capital HTX.

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


View All Listings